CCO
0.003
50%
NAE
0.001
-50%
M2R
0.003
50%
AOK
0.002
-33.3%
TOU
0.003
50%
ARV
0.003
-25%
AVE
0.021
40%
MQR
0.006
-25%
BLU
0.004
33.3%
KM1
0.08
-23.8%
HIQ
0.008
33.3%
COI
0.1
-23.1%
HYD
0.004
33.3%
AHN
0.004
-20%
M2M
0.01
25%
KTA
0.004
-20%
TGH
0.02
25%
XGL
0.008
-20%
BNZ
2.63
24.1%
BTE
0.04
-18.4%
UM1
0.145
20.8%
NOR
0.031
-18.4%
LKO
0.615
20.6%
LIS
0.115
-17.9%
AZI
0.024
20%
AVD
0.1
-16.7%
SIX
0.084
20%
ENL
0.005
-16.7%
NH3
0.11
17%
FEL
0.005
-16.7%
AM5
0.007
16.7%
RBX
0.03
-16.7%
GLL
0.007
16.7%
VIT
0.022
-15.4%
LMG
0.014
16.7%
T3D
0.035
-14.6%
PL9
0.007
16.7%
BNL
0.006
-14.3%
SIS
0.007
16.7%
MEM
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts